PROTEOME SCIENCES PLC (PRM) — Final Results for the Year Ending 31st December 2024

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the PROTEOME SCIENCES PLC final results investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged, they can be submitted at any time by the q and a tab situated in the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives in the meeting itself. However, the company can review the questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to the executive chairman, Christopher Pierce. Good morning to you, sir. Good morning. Thank you very much indeed. I thought that I would start the shareholder presentation today with a brief overview of the final results that we announced yesterday. Firstly, I'll just cover the initial dis the normal disclaimer, and, I will now go lead off. Against a difficult economic and industry background, in the first half of twenty twenty four, our PROTEOME SCIENCES business was adversely affected by the challenging background to the biotech and pharma markets with reduced r and d budgets out there and continued postponements of projects which carried over from 2023. First half revenue declined by 31% to 2,220,000 compared with 3,210,000 in 2023. Following the 1,000,000 reduction in revenues in the interim results, the, as anticipated at that time, things rebounded with a 47% increase in the second half to 2,670,000 versus the 1,820,000 in the similar period in 2023 with full year revenue for the year to December 2024 recovering to 4,890,000 versus the 5 point naught 3,000,000 we had in 2023. This reflected the strong increases in services orde...